ABNOM
☆ AI Dermatology — Free Service
Kwiziphumo zika-2022 ze-Stiftung Warentest ezivela eJamani, ukwaneliseka kwabathengi ngeModelDerm bekungaphantsi kancinci kunokubonisana nge-telemedicine ehlawulweyo.
Kwiziphumo zika-2022 ze-Stiftung Warentest ezivela eJamani, ukwaneliseka kwabathengi ngeModelDerm bekungaphantsi kancinci kunokubonisana nge-telemedicine ehlawulweyo.
relevance score : -100.0%
ReferencesI‑Q-switched Nd:YAG laser yaziwa ngokunyanga i‑nevus ye‑Ota kunye neemeko ezifanayo. Siqhube isifundo ukuze sibone indlela i‑high‑fluence 1064 nm Q‑switched Nd:YAG laser esebenza ngayo kwiindawo ezingaqhelekanga zaseMongolia, ngaphandle kokubangela ukuba ulusu lube lula. Sifunde izigulane ezingama‑61 ezinala‑mabala, sivavanya zonke izilonda ezili‑70. Isiqingatha sezo zilonda saphathwa nge‑laser, ngelixa ezinye zishiywe zingaphathwanga ukuze zithelekiswe. Sivavanye iziphumo sisebenzisa isikali kunye nesixhobo esibizwa ngokuba yi‑Mexameter® ukulinganisa amanqanaba e‑melanin. Izigulane zalandelwa umyinge weenyanga ezili‑14 kwiqela lonyango kunye neenyanga ezili‑18 kwiqela lokujonga. Ekupheleni kophando, sifumene umahluko omkhulu kumanqaku esikali kunye namanqanaba e‑melanin phakathi kwamaqela aphathwayo kunye namaqela angaphathwanga, kwaye iqela eliphathwa nge‑laser libonisa iziphumo ezingcono. I‑high‑fluence Q‑switched Nd:YAG laser, ngaphandle kokubanga ukukhanya kolusu, ibonakala isebenza kwaye ikhuselekile ekunyangeni ezi ndawo ezingaqhelekanga zaseMongolia.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
Sifunde ukusebenza kunye nokhuseleko lokusebenzisa unyango oluthile lwe‑laser i‑ABNOM, kwaye sabona ukuba zeziphi izinto ezinokuchaphazela indlela esebenza ngayo. Sijonge izigulane ezili‑110 ezisebenzise i‑ABNOM, kwaye zafumana phakathi kwesibini nesithoba zonyango lwe‑laser. Sifumanise ukuba unyango lusebenza ngcono xa lwenziwa ixesha elide, kodwa alusebenzi kangako kwizigulane ezindala. Kwakhona, lwasebenza ngcono kwizigulane ezinesikhumba esikhanyayo (uhlobo lwe‑III) kunye neendawo ezincinci ezichaphazelekayo (ngaphantsi kwe‑10 cm²). Ukuba ne‑melasma kunye ne‑ABNOM kwenza ukuba unyango lungasebenzi. Umbala okanye inani leendawo ezichaphazelekayo alikhange lenze umahluko. Malunga ne‑10 % yezigulane ziye zafumana iindawo ezimnyama emva konyango. Unyango lwangoku lunike iziphumo ezilungileyo. Izigulane ezindala ezinolusu olumnyama kunye namachokoza amnyama kunokwenzeka ukuba zibe namabala amnyama emva konyango. Kwizigulane ezine‑ABNOM kunye ne‑melasma, kungcono ukusebenzisa i‑laser yamandla asezantsi ukunqanda ukuba i‑melasma ibe mandundu.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ Unyango
Iiarhente ezimhlophe azifane zincede. Ngokungafani ne‑melasma, i‑ABNOM inokuphuculwa ngonyango lwe‑laser kwaye ishiywe ukuba isuswe ngaphandle kokuphinda. Unyango lwe‑laser lunokwenziwa ngamaxesha angama‑10 ukuya kuma‑20 ukunyanga i‑ABNOM.
#QS1064 laser